Insights and impacts from the TALOS-AMI Trial
Watch Prof. Dirk Sibbing discussing key takeaways from the TALOS-AMI trial data released at the LBT session.
574835_-_V2_Dirk_Sibbing_-_Insights_and_Impacts_
MAT-BH-2300392/V1/JUN2023
Campus
- Science
- Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
- Allergic Rhinitis
- Anti-Infectives
- Asthma
- Atopic Dermatitis
- Chronic Obstructive Pulmonary Disease
- Diabetes
- Eosinophilic Esophagitis
- Microbiota & Probiotics
- Multiple Myeloma
- Multiple Sclerosis
- Neurological Disorders
- Prurigo Nodularis
- Rare Diseases
- Transplant
- Nasal Polyps
Campus
- Science
- Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
- Allergic Rhinitis
- Anti-Infectives
- Asthma
- Atopic Dermatitis
- Chronic Obstructive Pulmonary Disease
- Diabetes
- Eosinophilic Esophagitis
- Microbiota & Probiotics
- Multiple Myeloma
- Multiple Sclerosis
- Neurological Disorders
- Prurigo Nodularis
- Rare Diseases
- Transplant
- Nasal Polyps
- It's Praluent of Course
- Of Course
- What is PRALUENT®?
- Why choose PRALUENT®?
- How to use PRALUENT®?